Aclaris Therapeutics Announces Positive Results in Phase 2

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Aclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts  

MALVERN, Pa., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS ), a clinical-stage specialty pharmaceutical company, today announced positive results from its Phase 2 clinical trial (WART-201), of A-101 Topical solution (A-101) for the treatment of common warts (verruca vulgaris).  A-101 is a proprietary formulation of high-concentration hydrogen peroxide currently under development as a prescription treatment for common warts.

WART-201 was a randomized, double-blind, vehicle-controlled, clinical trial designed to evaluate the safety and dose-response of 2 concentrations of A-101 Topical solution, 40% and 45%, compared with placebo (vehicle) in patients with common warts.  Ninety-eight patients were enrolled in the study with 90 patients completing eight weekly treatments at six investigational centers within the United States. 

In the trial, the 45% concentration of A-101 demonstrated clinically relevant and statistically significant improvement in the mean change in the Physician’s Wart Assessment (PWA) score and in complete clearance of common warts.  The side effect profile was similar to placebo.

WART-201 Efficacy Results:

  • The primary endpoint was the mean change from baseline in the PWA score one week after the last treatment.  Patients treated with 45% concentration A-101 demonstrated a statistically significant change in PWA score versus placebo (p=0.01).   
  • The secondary endpoints included two responder analyses: the proportion of patients whose target wart was judged to be clear on the PWA scale; and the proportion of patients whose target wart was judged to be either clear or barely evident on the PWA scale.
    • A-101 45% Topical solution achieved statistically significant complete clearance of the target wart one week after the last treatment versus placebo (p=0.02).
    • The proportion of target warts treated with A-101 45% Topical solution achieving a score of clear or barely evident one week after the last treatment was also statistically significant versus placebo (p=0.02).

WART-201 Safety Results:

  • A-101 was well-tolerated and local skin reactions (LSR) were primarily mild in severity and similar to placebo. The most frequently reported LSR across treatment groups was mild erythema.

“We are extremely pleased with these results,” said Dr. Neal Walker, President & CEO of Aclaris.  “This is an important milestone for our A-101 development program and substantiates the clinical value of our proprietary formulation of A-101 Topical solution.  Based on these results, we plan to continue the development of the 45% concentration of A-101 as a potential treatment for common warts.”

About Common Warts (Verruca Vulgaris) Warts are benign skin growths which appear when human papillomavirus (HPV) infects the top layer of the skin.  On an annual basis, 1.9 million people are diagnosed with common warts and although the warts are generally not harmful and in most cases eventually clear without any medical treatment, they may be painful, aesthetically unattractive, and are contagious.  Common warts can be removed with slow-acting, over-the-counter products containing salicylic acid.  Cryosurgery is the most frequently used in-office treatment for common warts.  No prescription drugs have been approved by the FDA for the treatment of common warts.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology.  Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting Aclaris’ website at www.aclaristx.com .

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of Aclaris’ A-101 drug candidate for the treatment of common warts. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2015, Aclaris’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, and other filings Aclaris makes with the SEC from time to time. These documents are available under the “Financial Information” section of the Investors page of Aclaris’ website at http://www.aclaristx.com . Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 mtung@aclaristx.com Media Contact Mariann Caprino TogoRun 917-242-1087 M.Caprino@togorun.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 157

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 161

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
LA Hospitals Shine in Pulmonary Excellence Nationwide

Updated Category News Views 135

Los Angeles Community Hospitals' Recent Recognition You ever stroll into a hospital and wonder if you’re really getting the best care? Well, the folks over at Los Angeles Community Hospitals, covering LA, Norwalk, and Bellflower, just got a big nod from Healthgrades—yeah, the site everyone's checking to find decent healthcare options. They’ve landed among the top...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 69

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 87

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 183

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 242

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 132

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 217

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 148

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading

Top 5 Most Recently Viewed Articles

Compugen's Q4 2025 Results: Is CGEN Set for a Rebound?

Updated Category News Views 168

Compugen Ltd. (NASDAQ: CGEN) is gearing up for its fourth quarter and full-year 2025 financial results set to drop on March 2, 2026, before U. S. markets open. You know how it goes—traders are already sizing up this number drop, trying to parse out if there’s any upside left or if it's just another 'waiting for Godot' situation. Compugen has been riding the waves of...

Continue Reading
Procyon Partners Appoints Rich Franchella to Propel Growth Strategy

Updated Category News Views 384

Procyon Partners' Strategic Growth Through Leadership Appointment Procyon Partners is excited to announce a significant addition to its leadership team with the appointment of Rich Franchella as the Senior Vice President of Business Development. This newly established role is aimed at catalyzing the firm’s growth trajectory and is set to bolster its efforts in...

Continue Reading
SMC Entertainment Expands Horizons With Bateau Acquisition

Updated Category News Views 162

SMC Entertainment Enhances Its Market Position SMC Entertainment, Inc. has taken a significant step in broadening its reach within the financial services sector by acquiring Bateau Asset Management. This strategic move paves the path for SMC to tap into the Australian and Southeast Asian markets, expanding its footprint in the dynamic world of fintech. An Overview of...

Continue Reading
Dustin Moskovitz Expands Asana Holdings with Major Purchase

Updated Category News Views 503

Dustin Moskovitz Expands His Investment in Asana Facebook co-founder Dustin A. Moskovitz, who currently holds the position of Director at Asana, Inc., has recently made headlines by increasing his stake in the company through the acquisition of 225,000 shares. This move highlights his ongoing commitment to the growth and success of Asana. Details of the Share Purchase The...

Continue Reading
GDMining's Innovative Cloud Mining Service Redefines Accessibility

Updated Category News Views 146

GDMining Expands Global Reach with Free Cloud Mining Service The cryptocurrency market is constantly evolving, and GDMining is leading the charge. This innovative platform offers an exciting opportunity for individuals around the globe to earn income from home through its unique cloud mining services. What sets this initiative apart is that it requires no initial...

Continue Reading